Five things for pharma marketers to know: Friday, February 27

Five things for pharma marketers to know: Friday, February 27

Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.

PCORI explains how it will release comparative-effectiveness findings

PCORI explains how it will release comparative-effectiveness findings

The organization plans to publish a scientific and a lay abstract detailing study findings

Sanofi's new Lantus may not be the new Lantus

Sanofi's new Lantus may not be the new Lantus

Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.

Drugmaker shifts sales model to keep pace with formulary decision making

Drugmaker shifts sales model to keep pace with formulary decision making

Some IDNs are centralizing decisionmaking at the corporate level and other hospitals are limiting on-site access to sales reps.

Concerns over Vyvanse marketing prior to approval: NYT

A report by the New York Times, citing a lack of an advisory committee for Vyvanse and illegal marketing lawsuits resolved last year, expressed concerns that the drug for binge-eating disorder will be overprescribed.

BI rare-disease awareness push slated for Saturday

Industry rare disease awareness efforts included a pipeline overview at Pfizer as well as BI's efforts to draw attention to IPF.

Lilly Lantus biosimilar to hit EU

The EU will have access to the new medication in May.

CDC finds patients using more potent opioids

The survey shows the use of stronger-than-morphine painkillers has jumped.

Five things for pharma marketers to know: Thursday, February 26

Five things for pharma marketers to know: Thursday, February 26

Sanofi's Lantus predecessor nabs approval; Pharmacyclics reportedly vets acquisition offers; FDA biosimilar hearing is postponed.

Poll shows all ages seek digital health tools

Poll shows all ages seek digital health tools

Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.

Mobile carries WebMD forward

Mobile carries WebMD forward

Smartphones drove network traffic.

GSK re-launches OTC diet pill

The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.

Five things for pharma marketers to know: Wednesday, February 25

Five things for pharma marketers to know: Wednesday, February 25

J&J loses another Risperdal case; Pfizer slashes jobs at research center; Actavis challenges ulcerative colitis drug's patent.

Global cancer drug market to grow to $111 billion by 2020: report

Global cancer drug market to grow to $111 billion by 2020: report

The global cancer market is expected to reach $111 billion by 2020, according to new market research, with immunotherapies—particularly in lung cancer—expected to drive growth.

California ponders drug pricing reveal

Assemblyman David Chiu's bill would publish a drug's R&D and related costs.

UK doctors lobby for off-label Avastin use

Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Lilly peglispro delay may be boon for its biosimilar

Lilly peglispro delay may be boon for its biosimilar

The drugmaker wants to put the drug through additional liver-impact tests.

Survey shows docs shrug off Sunshine

A MedPanel survey indicates doctors have not changed their business practices since the Open Payments database went live.

AdAge: advertising's penalty box is empty

The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.

Five things for pharma marketers to know: Monday, February 23

Five things for pharma marketers to know: Monday, February 23

Valeant grabs Salix for $10.4 billion, BMS inks to collaborations deals and Pfizer lines up to have the first treatment for a rare lung disease.

Five things for pharma marketers to know: Friday, February 20

Five things for pharma marketers to know: Friday, February 20

23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.

Poll highlights cholesterol knowledge gap

Poll highlights cholesterol knowledge gap

Americans may be taking anti-cholesterol medications, but it doesn't mean they are aware of their impact.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

An NIH study shows possible limit to Lucentis's appeal.

McNeil consumer president named HBA Woman of the Year

The Healthcare Businesswomen's Association named Denice Torres, president of J&J's McNeil Consumer Healthcare, as its 26th Woman of the Year.

Five things for pharma marketers to know: Thursday, February 19

Five things for pharma marketers to know: Thursday, February 19

Lilly delays Phase-III cholesterol drug results; PatientsLikeMe and Walgreens team up for "drug reaction reviews"; Roche skin-cancer drug receives Priority Review.

FDA expands Revlimid indication

Celgene's cancer drug is now approved for newly diagnosed patients.

AstraZeneca may give critic a seat at the table

Scientist Cori Bargmann's Twitter history makes the nomination a bit of a surprise.

Five things for pharma marketers to know: Wednesday, February 18

Five things for pharma marketers to know: Wednesday, February 18

Researchers find repeat marketing offenders in the UK and Sweden, Actavis plans to take Allergan's name and Sanofi enters an auto-immune disease collaboration.

Survey shows docs overestimate adherence

Survey shows docs overestimate adherence

A small physician survey shows doctors think their patients have higher adherence rates than the norm.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

Court invalidates patent for AstraZeneca asthma drug

A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.

Five things for pharma marketers to know: Tuesday, February 17

Five things for pharma marketers to know: Tuesday, February 17

Bayer exec may be Sanofi's new CEO, GSK gets a new North American Pharma lead, and Pfizer sends painkiller ALO-02 to the FDA.

Five things for pharma marketers to know: Friday, February 13

Five things for pharma marketers to know: Friday, February 13

FDA approves Eisai's thryoid cancer drug two months early, Gilead and Germany agree to a Sovaldi price cut, and Valeant looks set to make a bid for Salix.

Study shows impact of the "Angelina Jolie effect"

Study shows impact of the "Angelina Jolie effect"

AARP researchers found that the celebrity's decision to go public triggered a surge in genetic screening.

Pfizer teams up with Alzheimer's foundation

Pfizer's academic research arm will work together with the Alzheimer's Drug Discovery Foundation to jointly invest in scientific research to identify clinical candidates for testing.

Five things for pharma marketers to know: Thursday, February 12

Five things for pharma marketers to know: Thursday, February 12

Hospira is planning a Lucentis biosimilar, Roche is expanding is cancer diagnostics portfolio, and cholesterol may not be as bad as originally thought (but smoking is worse than ever).

GSK launches Flonase OTC

GSK launches Flonase OTC

The initial push includes a behind-the-scenes Tumblr and broadcast plans are being finalized.

Sanofi lays off 100 at Boston R&D hub

The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.

Five things for pharma marketers to know: Wednesday, February 11

Five things for pharma marketers to know: Wednesday, February 11

BMS loses breakthrough therapy status, Gilead's pricing comes under fire in Europe, and pharma fights Italy's off-label Avastin use.

OPDP finds many flaws with Luitpold video

OPDP finds many flaws with Luitpold video

The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.

Merck Januvia survey sparks ethics debate

A Merck survey that indicated distaste for British Columbia's decision to boot Januvia from the formulary has stirred up debate over bias.

Five things for pharma marketers to know: Tuesday, February 10

Five things for pharma marketers to know: Tuesday, February 10

FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.

Five things for pharma marketers to know: Monday, February 9

Five things for pharma marketers to know: Monday, February 9

Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.

Five things for pharma marketers to know: Friday, February 6

Five things for pharma marketers to know: Friday, February 6

Genentech Parkinson med encounters preliminary safety issues; Cigna gives Gilead's Harvoni preferred status over AbbVie's Viekira Pak; Valeant proposes $400 million bid to buy bankrupt Dendreon.

Pfizer's Hospira deal shores up established product division

Pfizer's Hospira deal shores up established product division

Pfizer said the $17-billion decision to acquire Hospira will not affect the timeline of its divide-or-stay-whole decision.

Survey shows cancer cause-effect awareness lacking

A survey showed patients are not really clear on what causes cancer.

Five things for pharma marketers to know: Thursday, February 5

Five things for pharma marketers to know: Thursday, February 5

FDA commissioner Margaret Hamburg has stepped down; Pfizer acquires Hospira for $15.2 billion, AstraZeneca buys Actavis's branded respiratory business.

FDA rescinds Merck HCV therapy's Breakthrough Designation

FDA rescinds Merck HCV therapy's Breakthrough Designation

The drugmaker announced in its earnings call Wednesday that the FDA has rescinded the company's Breakthrough Therapy designation, which could delay Merck's HCV doublet therapy launch from early to mid-2016.

Pfizer Ibrance is first approved CDK inhibitor

Pfizer Ibrance is first approved CDK inhibitor

The FDA approved the breast cancer drug Tuesday afternoon. Estimated peak sales: $3.8 billion.

FDA simplifies compassionate use application

The original required 26 bits of information and seven attachments.

Five things for pharma marketers to know: Wednesday, February 4

Five things for pharma marketers to know: Wednesday, February 4

One in three adults would rather not take a pill and have a shorter life span; Pfizer's next-gen breast-cancer drug nabs an early approval; Amgen's Humira biosimilar demonstrates clinical equivalence.

Education effort provides measles/pertussis cheat sheet

Education effort provides measles/pertussis cheat sheet

Measles outbreak news aside, doctors need help identifying illnesses vaccines have made uncommon.

Study says pharma may need profit-sustaining help

Study says pharma may need profit-sustaining help

Researchers say the golden-age of profits appears to be over, and the industry may need help funding innovation.

CDC: diabetes patient costs have doubled

The reason: higher prices and more services.

Ireland takes hard line on Rx prices

The health minister is threatening price-related legislation.

Education efforts key to Vyvanse success in BED, analyst says

Education efforts key to Vyvanse success in BED, analyst says

Shire's ADHD treatment Vyvanse won a label expansion into treating moderate-to-severe binge-eating disorder (BED) Friday. One analyst says that disease awareness and detailing efforts are crucial to the drug's commercial plans in the category.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Five things for pharma marketers to know: Monday, February 2

Five things for pharma marketers to know: Monday, February 2

Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.

Five things for pharma marketers to know: Friday, January 30

Five things for pharma marketers to know: Friday, January 30

Obama's precision medicine initiative looks set for bipartisan support, Valeant has offered $296 million to buy Dendreon and researchers say Roche's Tamiflu works.

Researchers find payer discrimination

Researchers found that 25% of ACA-compliant plans put HIV drugs in the highest formulary tier.

Alexion, Treato shuffle staff

Alexion's CEO Leonard Bell is retiring, and TripAdvisor's Christine Peterson has joined Treato.

J&J's Imbruvica snares fourth indication

J&J's Imbruvica snares fourth indication

The label will now include Waldenstrom's macroglubulinemia.

Five things for pharma marketers to know: Thursday, January 29

Five things for pharma marketers to know: Thursday, January 29

Former FDA chief tells court J&J knew of Risperdal risk, pay-for-delay deals get new court criteria, lawmakers may declare pharmacists healthcare providers.

Biogen adds football, basketball talent for MS campaign

Biogen adds football, basketball talent for MS campaign

MS drugmaker Biogen Idec drafted Tyler Campbell, son of NFL Hall of Fame running back Earl Campbell, and former Dallas Mavericks point guard Chris Wright to help inspire sufferers of multiple sclerosis.

Amgen, Novartis, BMS map future

Amgen, Novartis, BMS map future

Amgen execs assert there is still a future for 15-year-old Enbrel, Novartis sees off-label Avastin use pinch Lucentis sales and BMS has expanded its field force in anticipation of an Opdivo push.

Five things for pharma marketers to know: Wednesday, January 28

Five things for pharma marketers to know: Wednesday, January 28

Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.

Purdue's new Rx opioid hits market

Purdue's new Rx opioid hits market

Hysingla ER is ready for the marketplace, just two months after FDA approval.

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

Pfizer quarter and year sales slip, CEO indicates M&A not pressing

CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.

Drugmaker enlists Fitbit to better understand patients

Biogen Idec handed out 250 Fitbits last year to better understand how MS affects patients' mobility, and how its medications hinder disease progression.

Five things for pharma marketers to know: Tuesday January 27

Five things for pharma marketers to know: Tuesday January 27

AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.

NPS drug approval bolsters Shire acquisition decision

NPS drug approval bolsters Shire acquisition decision

The FDA approved NPS Pharmaceuticals's rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.

Sanofi, Regeneron officially in PCSK9 race

Sanofi, Regeneron officially in PCSK9 race

The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

New cancer therapies raise new safety concerns

Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.

Five things for pharma marketers to know: Monday, January 26

Five things for pharma marketers to know: Monday, January 26

Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.

Actavis CEO touts his acquisition strategy

Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Guidemark Health jumpstarts rebrand, brings on big-agency grad

Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.

Five things for pharma marketers to know: Thursday, January 22

Five things for pharma marketers to know: Thursday, January 22

Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.

Novartis psoriasis drug approval could upend market

Novartis psoriasis drug approval could upend market

A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.

Merck to end US Victrelis distribution this year

The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.

Nurse practitioner workforce has just about doubled

Marketers may want to dust off plans to create NP-centric materials.

Sandoz gets ready to make the biosimilar case with oncologists

Sandoz gets ready to make the biosimilar case with oncologists

Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.

J&J Q4 sales slip, but year finishes up 4.2%

J&J Q4 sales slip, but year finishes up 4.2%

Despite growth, some disappointment lurks in the numbers -- possibly for hepatitis C medication Olysio.

Supreme Court says Teva MS patent stands (for now)

The ruling stalls generics until at least September.

Five things for pharma marketers to know: Tuesday, January 20

Five things for pharma marketers to know: Tuesday, January 20

FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.

Five things for pharma marketers to know: Friday, January 16

Five things for pharma marketers to know: Friday, January 16

CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.

BI weighs sale of generic business

Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.

Abandonment rates indicate room in the anti-TNF market

Abandonment rates indicate room in the anti-TNF market

Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.

Better Rx coverage associated with outcomes lift: study

Better Rx coverage associated with outcomes lift: study

A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.

Roche's scuttled cholesterol drug may work

Clinical trials indicate the CETP works for specific genetic profiles.

Five things for pharma marketers to know: Wednesday, January 14

Five things for pharma marketers to know: Wednesday, January 14

Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.

FDA to study impact of shorter DTC risk list

FDA to study impact of shorter DTC risk list

The FDA is looking into whether abbreviated risk information is a good idea for DTC.

Five things for pharma marketers to know: Tuesday, January 13

Five things for pharma marketers to know: Tuesday, January 13

Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.

Pfizer challenges Novartis OTC ad claims

Pfizer challenges Novartis OTC ad claims

Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'

News hints at BMS-Merck PD-1 lung cancer tussle

News hints at BMS-Merck PD-1 lung cancer tussle

News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.

NFL players promote Healthcare.gov

HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

Five things for pharma marketers to know: Monday, January 12

Five things for pharma marketers to know: Monday, January 12

BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters